Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex

Amyloid

Volumn 18, Issue SUPPL. 1, 2011, Pages 145-147

  Penot, A ^a   Abraham, J ^a   Debarri, H ^b   Desport, E ^a,c   Aguilar, C ^a,d   Lavergne, D ^a   Auroy, F ^a   Leleu, X ^b   Goldstein, A ^e   Kolb, B ^f   Bridoux, F ^a,e   Ermand, J P ^d   Leblond, V ^g   Jaccard, A ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e Centre de santé pluridisciplinaire   (France)

^f SERVICE DE DERMATOLOGIE   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LIGHT CHAIN; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL;

EID: 79960007599     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2011.574354     Document Type: Article

References (9)

1. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, et al. Highdose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-1093. (Pubitemid 47443213)
2. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L, Merlini G. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110:787-788. (Pubitemid 47105419)
3. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidisis. Blood 2007;1092:465-470. (Pubitemid 46105939)
4. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105:2949-2951. (Pubitemid 40446290)
5. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351-1358. (Pubitemid 350144152)
6. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93:295-298. (Pubitemid 351397721)
7. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, et al. VELCADE CAN 2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 doseescalation study. Blood 2009;114:1489-1497.
8. Nowis D, Maczewski M, Mackiecz U, Kujava M, Ratajska A, Wieckowski MR, Wilczynski GM, Malinowska M, Bil J, Salwa P, et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010;176:2658-2668.
9. Orciuolo E, Buda G, Cecconi N, Galimberti S, Versari D, Cervetti G, Salvetti A, Petrini M. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 2007;138:396-397.